Therapeutic doses (75-300 mg/day, divided):

• Onset 30-60 min, peak 1-1.5 hr.
• Mild-to-moderate sedation, "calm," "anxiety-soft" feeling. Some report mood lift.
• ~4% of clinical trial patients spontaneously report euphoria — higher than virtually any non-controlled drug.
• Cognitive blunting common: reduced concentration, "slowed thinking," word-finding difficulty.

Higher therapeutic / supratherapeutic (300-900+ mg):

• Marked sedation, motor incoordination, slurred speech.
• Euphoria intensifies, particularly in opioid-tolerant or benzodiazepine-experienced users — pregabalin "lights up" reward in ways naive users don't always experience.
• Disinhibition similar to alcohol or low-dose benzodiazepines.
• At very high doses (>900 mg recreational): dissociation, mild psychedelic-like effects, blackouts.

Tolerance: Develops fast. Recreational users commonly escalate from 600 → 900 → 1200+ mg within weeks. Therapeutic users describe needing dose increases to maintain anxiolysis within 4-12 weeks.

Withdrawal (clinically severe — comparable to benzodiazepines):

• Onset 24-48 hr after last dose with chronic use.
• Anxiety rebound (often worse than baseline), insomnia, sweating, tremor, tachycardia, palpitations, headache, nausea, GI distress.
• Severe cases: seizures, suicidal ideation, psychosis, hallucinations (auditory most common), depersonalization, profound depression.
• Duration: acute 1-2 weeks, protracted symptoms can persist months.
• Tapering required for any chronic user — no abrupt discontinuation. Standard taper is 10-25% per week; severe-dependence cases use diazepam bridge protocols (PMC 8764940).

• Tolerance buildup: fast. Clinical anxiolytic tolerance within weeks. Recreational tolerance within days.
• Cycling: not viable for the use cases people actually want pregabalin for. Anxiolysis and pain control require steady-state dosing; cycling reintroduces withdrawal each off-cycle.
• Reset protocol: Full discontinuation taper (4-12 weeks) with possible diazepam bridge for severe cases. Cross-tolerance with gabapentin and possibly other GABAergic-adjacent drugs.

Synergistic with (use-case-specific, not endorsements)

• Opioids: dangerous synergy at any dose; only intentional in carefully managed perioperative or palliative settings.
• SSRIs/SNRIs (for GAD adjunct): clinically used; additive anxiolysis with manageable interaction profile.

Avoid stacking with

• phenibut — same broad sedative-anxiolytic family with overlapping dependence profile, GABA-B vs α2δ but additive CNS depression and additive withdrawal severity.
• baclofen — CNS depression stacking, both produce withdrawal syndromes.
• gabapentin — same mechanism, no benefit to combining; just dose pregabalin.
• alcohol, benzodiazepines, opioids, z-drugs, daridorexant — all CNS depressants with respiratory or sedation stacking risk.
• caffeine as a "balancer" — masks sedation, leading users to underestimate impairment.

Neutral / safe co-administration

• No CYP interactions, so most nootropics and supplements are pharmacokinetically clean.
• The risk is pharmacodynamic (CNS depression stacking), not metabolic.

• No CYP induction or inhibition. No protein binding. Renal-cleared unchanged.
• Pharmacodynamic: additive CNS depression with all sedatives, opioids, alcohol, antihistamines, antipsychotics.
• ACE inhibitors: increased angioedema risk reports.
• Thiazolidinediones (pioglitazone, rosiglitazone): additive edema/weight gain.
• Hormonal contraceptives: no clinically significant interaction.

• No major CYP polymorphism relevance (drug bypasses hepatic metabolism).
• α2δ-1 (CACNA2D1) polymorphisms may modulate response — research-grade, not clinically actionable in 2026.
• Renal function genetics (any condition impacting eGFR) directly affects exposure.

Sourcing isn't the bottleneck for users in this archetype; the medical case is. And there is no medical case for nootropic use.

• Baseline: weight, BP, eGFR/creatinine clearance, mood-VAS, anxiety-VAS, sleep quality, suicide screen (PHQ-9 item 9 or C-SSRS).
• During use:
  • Weight: weekly first 4 weeks, then monthly
  • eGFR: every 3-6 months (especially if any renal risk factor)
  • Mood + suicidal ideation screening: 2 weeks, 4 weeks, then quarterly (FDA black-box class)
  • Sedation/cognitive impact: subjective VAS at 1 week, 4 weeks
  • Misuse markers: dose-creep requests, between-prescriber doctor-shopping, missed-dose distress
• Discontinuation: track withdrawal symptoms across full taper window (4-12 weeks); reassess underlying indication at end of taper.